NCT06226012 is a NA clinical trial of pulsed magnetic field in Juvenile Idiopathic Arthritis, sponsored by Shrouk Abd Elmohsen Taha Basiony Elnhrawy.

Who is sponsoring NCT06226012?

NCT06226012 is sponsored by Shrouk Abd Elmohsen Taha Basiony Elnhrawy.

What drugs are being tested in NCT06226012?

Interventions in NCT06226012: pulsed magnetic field, Low level laser.

What condition does NCT06226012 study?

NCT06226012 studies Juvenile Idiopathic Arthritis.

Is NCT06226012 still recruiting?

NCT06226012 is currently completed. Last updated 26 January 2024.

Last reviewed 2024-01-26 · How we verify

NCT06226012

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Pulsed Magnetic Field Versus Low Level Laser Therapy on Functional Performance in Children With Juvenile Idiopathic Arthritis

Completed NA Last updated 26 January 2024

What this trial tests

NA trial testing pulsed magnetic field in Juvenile Idiopathic Arthritis in 40 participants. Completed in 1 August 2023.

Timeline

1 May 2023

Primary endpoint
1 August 2023

1 August 2023

Quick facts

Lead sponsor	Shrouk Abd Elmohsen Taha Basiony Elnhrawy
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	40
Start date	1 May 2023
Primary completion	1 August 2023
Estimated completion	1 August 2023
Sites	1 location across Egypt

Drugs / interventions tested

pulsed magnetic field
Low level laser

Conditions studied

Juvenile Idiopathic Arthritis — all drugs for Juvenile Idiopathic Arthritis →

Sponsor

Shrouk Abd Elmohsen Taha Basiony Elnhrawy

Who can join

Adults 8 to 16, any sex, with Juvenile Idiopathic Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

the purpose of this study is to compare between the effect of pulsed magnetic field versus low level laser therapy on functional performance in children with juvenile idiopathic arthritis

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Juvenile Idiopathic Arthritis

Currently open trials in the same condition.

NCT07243782 — Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cose · recruiting
NCT05879419 — Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases · Phase 4 · active not recruiting
NCT06007456 — Clinical, Laboratory and Ultrasound Stratification of Patients With Juvenile Idiopathic Arthritis · recruiting
NCT03913962 — Health and Exercise Response in Children With Chronic and Auto-immune Pathologies · NA · recruiting
NCT06560606 — UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06226012 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shrouk Abd Elmohsen Taha Basiony Elnhrawy
Last refreshed: 26 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06226012.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing